USPTO Patent Applications - Organic Chemistry (C07D)

Aldose Reductase Inhibitors for Skin Aging and Cardiovascular Disorders

USPTO published patent application US20260092072A1 by inventor Andrew WASMUTH for aldose reductase inhibitor compounds. The application covers novel pharmaceutical compositions for treating skin aging, cardiovascular disorders, renal disorders, cancer, diabetes complications, and related conditions. The filing (Application No. 19414626) was submitted December 10, 2025, and classified under CPC codes C07D 495/04 and C07H 15/26.

Substituted Indazoles IRAK4 Inhibitor Patent Application

The USPTO published patent application US20260092069A1 by inventors Terstiege, Schiesser, Xue, Chang, and Berggren for substituted indazoles as IRAK4 inhibitors with potential therapeutic utility. The application (No. 19343252) was filed September 29, 2025 and published April 2, 2026. IRAK4 inhibitors target inflammatory and autoimmune pathways.

Novel Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092073A1 by Hoffmann-La Roche Inc. for novel heterocyclic compounds with general formula I, including compositions and methods of use. The application (Filing Date: 2025-10-15) covers compounds where R1, R2, R9, A1, Rx and Ry define specific substituents. Inventors include David BON, Lea Aurelie BOUCHE, Wolfgang GUBA, and others. CPC Classification: C07D 498/04.

Annelated Pyridines as Steroidogenesis Inhibitors

USPTO published patent application US20260092074A1 by Hoffmann-La Roche covering annelated pyridine compounds as steroid synthetase inhibitors for pharmaceutical use. The application, filed September 25, 2023, discloses small-molecule heterocyclic compounds (C07D class) with applications in steroid hormone regulation. Inventors include Qingzhong Hu, Lina Yin, and Haiyan Li.

Broad Spectrum Antiviral Compositions and Methods

The USPTO published patent application US20260092059A1 by Evrys Bio, LLC covering novel thiazole- and isoquinoline-containing compounds for treating broad-spectrum viral infections. The compounds demonstrated inhibition of HCMV, influenza viruses, Zika virus, BK Virus, and RSV in cell-based assays. The application (No. 19342999) was filed September 29, 2025, and published April 2, 2026.

Isotopically enriched psychedelic analogs for brain disorders

The USPTO published patent application US20260092060A1 for isotopically enriched analogs of 2-bromo-LSD, LSD, ALD-52, and 1P-LSD developed by inventors Matthew Duncton and Samuel Clark. The compounds are directed toward treating neurologic and brain disorders. The application was filed on June 5, 2025, under Application No. 19228993.

Heterocyclic Compounds for Treatment of Disease

USPTO published patent application US20260092064A1 for heterocyclic compounds and compositions for treating disease, filed by inventors Raju Mohan, John Nuss, and Jason Harris on May 14, 2025. The application was published April 2, 2026, covering compounds classified under CPC codes including C07D 471/04, A61K 31/41, and A61P therapeutic categories.

PRC2 Inhibitor Patent for Cancer Treatment, Forms

USPTO published patent application US20260092068A1 for physical forms of PRC2 inhibitor compounds for cancer treatment. Inventors: Mohammad AL-SAYAH and Robert Ronald MILBURN. Application filed September 13, 2023, classified under C07D 487/04 (heterocyclic compounds - organic chemistry). The patent covers the physical forms, pharmaceutical compositions, and methods of treating cancer by administering the compound.

Method for Preparing Amidines from N-(alkyl lactams) via Dehydration Catalysis

USPTO published patent application US20260092067A1 disclosing a method for preparing amidines from N-(amino-alkyl) lactams via dehydration using heterogeneous catalysts including cerium oxide, boron phosphates, zirconium compounds, and phosphotungstic acid. The application (No. 19108987) was filed September 4, 2023 and published April 2, 2026, listing inventors Nicola Vecchini and Federico Mondini. This represents a new synthetic route for amidine compounds used in pharmaceutical and fine chemical synthesis.

Crystalline Solid Forms of BET Inhibitor for Cancer Treatment

The USPTO published patent application US20260092065A1 for crystalline solid forms of BET protein inhibitors (BRD2, BRD3, BRD4, BRD-t) useful in cancer treatment. Seven inventors (Chen, Jia, Liu, Qiao, Wu, Zhou, Li) filed the application on September 23, 2025. The application claims novel solid forms, preparation methods, and intermediates for the therapeutic compound.

Novel synthetic routes for macrocyclic heterocycle manufacturing

USPTO published patent application US20260092066A1 on April 2, 2026, disclosing novel synthetic methods for preparing macrocyclic heterocycle intermediates. The application (filed June 18, 2025, Application No. 19242506) covers efficient methods for synthesizing key intermediates in the preparation of Compound (I) with broad substituent applicability.

Fused Bicyclic RAF Inhibitors and Methods for Use Thereof

The USPTO published patent application US20260092063A1 for fused bicyclic RAF inhibitors as potential cancer therapeutics, including colorectal cancer treatment. Inventors include Andrew Belfield, Clifford David Jones, Jean-François Margathe, and Chiara Colletto. The application was filed on 2025-05-12 under Application No. 19205876.

Pyridine Carboxamide Compounds for Treating Medical Conditions

The USPTO published patent application US20260092062A1 for pyridine carboxamide compounds and their use in treating medical conditions. The application was filed by inventors Todd Bosanac, Nathan Oliver Fuller, Robert Owen Hughes, Guy Bemis, and Janeta Valentina Popovici Muller on September 26, 2023, and published on April 2, 2026.

Seven inventors file PROTAC protein degradation compounds patent

Seven inventors file PROTAC protein degradation compounds patent

Small Molecule Degraders and Fluorescent Probes of PXR

USPTO published patent application US20260092058A1 disclosing compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention relates to decreasing adverse drug reactions associated with administration of anticancer agents, antibacterial agents, non-steroidal anti-inflammatory agents, or anticonvulsant agents. Application No. 18902844 was filed September 30, 2024.

BCL-XL/BCL-2 Degraders and Uses Thereof

The USPTO published patent application US20260092057A1 for BCL-XL/BCL-2 degrader compounds and methods of using the same for treating conditions such as cancer. The application was filed on May 12, 2023, by inventors including Huijun Dong, Bin Yang, and others, and covers novel chemical compositions under CPC classifications including C07D 417/12, C07D 471/04, and related therapeutic uses.

Melanocortin-4 Receptor Agonists for Obesity and Diabetes Treatment

The USPTO published patent application US20260092056A1 for melanocortin-4 receptor agonists developed by eight inventors. The compounds of Formula 1 demonstrate agonist activity against melanocortin-4 receptors and may be useful in preventing or treating obesity, diabetes, inflammation, and erectile dysfunction.

Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof

USPTO published patent application US20260092055A1 by Zhejiang Hisun Pharmaceutical Co., Ltd. for aromatic acetylene derivatives useful as LpxC inhibitors for treating bacterial infections. The application covers the chemical compounds, preparation methods, and pharmaceutical compositions. Application No. 19112826 was filed September 28, 2023.

Fused Ring STAT6 Inhibitor for Atopic Dermatitis Treatment

The USPTO published patent application US20260092054A1 disclosing a fused ring compound with STAT6 inhibitory activity for treating atopic dermatitis and allergic diseases. Invented by Yoshitake Sumikawa, Issei Akahoshi, and Masaya Kato, the application (No. 19116232) was filed September 29, 2023 and published April 2, 2026. The claimed compound and pharmaceutical compositions target inflammatory conditions via STAT6 pathway inhibition.

KHK Inhibitor Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092053A1 for KHK (ketohexokinase) inhibitor heterocyclic compounds, filed August 22, 2025. The application includes nine inventors and covers compounds of a specified formula with variable substituents defined in the specification. The compounds are classified under multiple CPC categories including C07D 409/14, C07D 401/14, and related pharmaceutical compound classifications.

Muscarinic M1 Receptor Compound Treats Alzheimer Disease

USPTO published patent application US20260092052A1 for a nitrogen-containing heterocyclic compound functioning as a muscarinic M1 receptor positive allosteric modulator. The compound is intended for prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, and dementia with Lewy bodies. Inventors include Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, and Makoto Kamata. Application No. 19010914 was filed on January 6, 2025.

Pyrimidine Compounds for Cancer Prevention Treatment

The USPTO published patent application US20260092051A1 for pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers. Inventors include In Hwan Bae, Ji Sook Kim, Jae Yul Choi, and others. The application (No. 19203828) was filed on May 9, 2025, and published on April 2, 2026. This is an informational publication with no compliance requirements.

Chemokine receptor modulators and C07D heterocyclic compounds patent application

USPTO published patent application US20260092050A1 for chemokine receptor modulators and C07D heterocyclic compounds. The application discloses novel compounds for modulating chemokine receptor activity with potential therapeutic uses. Inventors include Parcharee Tivitmahaisoon, David J. Wustrow, Mikhail Zibinsky, and Omar Robles. Filing date was January 17, 2025.

Methods of Making Trans Isomeric Forms of G Protein-Coupled Receptor Modulators

The USPTO published patent application US20260092049A1 disclosing methods for synthesizing trans isomeric forms of G protein-coupled receptor (GPCR) modulators with high trans isomeric purity. The application names eight inventors and covers pharmaceutical compositions and synthetic routes for producing these receptor modulators. This publication establishes priority rights for the claimed invention under 35 U.S.C.

Quinoline cGAS Antagonist Solid Forms and Salts

The USPTO published patent application US20260092048A1 for solid forms and salts of a quinoline cGAS antagonist compound, filed by inventors Jian Qiu, Qi Wei, Heping Shi, Lijun Sun, and Zhijian Chen (Application No. 19316546, filed September 2, 2025). The application discloses the compound's cGAS antagonist properties, methods of preparation, pharmaceutical compositions, and use in medical therapy.

CFTR Modulator Patent, Pharmaceutical Compositions, Treatment Methods

The USPTO published patent application US20260092047A1 disclosing CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds of Formula (I), their pharmaceutical compositions, methods of treating cystic fibrosis, and processes for making the modulators. The application also covers solid state forms of Compound 1 and salts and solvates thereof. The application was filed on May 13, 2025, with Application No. 19206359.

Quinoline Butenamide Maleate Salts for EGFR Cancer Treatment

The USPTO published patent application US20260092046A1 covering maleate salt forms of a quinoline-based butenamide compound designed to target epidermal growth factor receptor (EGFR) family kinases for cancer treatment. Invented by Quinhong Lu and colleagues, the application discloses crystalline forms, preparation methods, and pharmaceutical compositions. The patent application was filed on May 5, 2025, and published on April 2, 2026.

Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors

The USPTO published patent application US20260092045A1 for substituted benzofuran, benzopyrrole, benzothiophene compounds and structurally related compounds as complement system inhibitors. The application was filed on December 8, 2025, with 11 named inventors including Pravin L. Kotian, Yarlagadda S. Babu, and Weihe Zhang. The compounds may be formulated as pharmaceuticals for treating diseases characterized by aberrant complement system activity.

Pyrimidine Derivative for Inflammation Treatment

USPTO published patent application US20260092044A1 by ASKA Pharmaceutical Co., Ltd. for a pyrimidine derivative with mPGES-1 inhibitory activity for treating inflammation, pain, and rheumatism. The application was filed December 8, 2025, and names Makoto Okada, Youichi Nakano, Takashi Nose, Satoshi Maeda, and Tomoaki Watanabe as inventors.

Novel Benzoxazole Derivative Comprising 4-Amino-Butanamide and Anti-Inflammatory Use

USPTO published patent application US20260092043A1 by EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION disclosing novel benzoxazole derivatives comprising 4-amino-butanamide and their anti-inflammatory pharmaceutical applications. The application (No. 19115423) was filed March 14, 2023 and published April 2, 2026.

Ipconazole preparation process patent

USPTO published patent application US20260092042A1 by inventors Mittal, Kini, Mukadam, and Shelkar disclosing a process for preparing Ipconazole, a triazole fungicide used in agriculture. The application, filed September 13, 2023, and published April 2, 2026, claims a cost-effective and environmentally friendly synthesis method suitable for large-scale industrial production.

Process for Preparing Fluoro-imino-dihydropyrimidine Compounds

The USPTO published patent application US20260092041A1 for Adama Makhteshim Ltd., covering a process for preparing fluoro-imino-dihydropyrimidine compounds and derivatives. The application was filed on 2025-10-08 under Application No. 19352947. Inventors include Gal Suez, Samaa Alasibi, and Yaakov Mines.

Cyclopropane Carboxylic Acid Synthesis Methods

The USPTO published patent application US20260092040A1 for methods of preparing substituted cyclopropane carboxylic acid compounds. Inventors Nikolaos Papaioannou, Michael Jonathan Fray, Andreas Rennhack, and Sarah Jocelyn Fink filed the application on September 20, 2023 (Application No. 19113778). The application covers synthetic routes for these chemical compounds, which have potential uses in pharmaceutical development.

Dual Inhibitors for Alzheimer's Disease Treatment

USPTO published patent application US20260092039A1 for dual inhibitors (soluble epoxide hydrolase and glutaminyl cyclase inhibitors) useful for Alzheimer's disease treatment. Inventors from Spain and Germany filed Application No. 19161626 on March 4, 2024, with the application published April 2, 2026. The compounds also reduce pro-inflammatory cytokines, exhibit low cytotoxicity, and have good blood-brain barrier permeability.

Crystalline T-type calcium channel salt patent

The USPTO published patent application US20260092036A1 by inventors Daniel Thomas Walters and Thomas San Ie on April 2, 2026. The application discloses Pattern D, a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1), along with pharmaceutical compositions and methods for treating neurological and psychiatric disorders. The application was originally filed on August 27, 2025, with application number 19311030.

7-Azaindole Analogs and Serotonin Agonists for Neurological Disorders

The USPTO published patent application US20260092034A1 for 7-azaindole analogs as serotonin receptor agonists for treating neurological disorders. Assigned to Kuleon LLC with inventor David Gilles, the application covers both hallucinogenic and non-hallucinogenic compounds. The patent application was filed December 8, 2025, under application number 19412382.

Hydrochloric acid salt of 5-HT2C agonist patent application

USPTO published patent application US20260091039A1 for a crystalline hydrochloric acid salt of (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (a 5-HT2C agonist). The application includes pharmaceutical composition claims and methods of use. Inventor: Anthony Clyde Blackburn. Application No. 19344622.

Ligand-Enabled Scalable C-H Hydroxylation of Benzoic and Phenylacetic Acids at Room Temperature

The USPTO published patent application US20260092029A1 by Yu/Quan et al. disclosing methods for Pd-catalyzed C-H hydroxylation of benzoic and phenylacetic acids at room temperature using bifunctional pyridone-carboxylic acid ligands and aqueous hydrogen peroxide as oxidant. The application, filed September 7, 2023, also covers synthesis of polyfluorinated natural products and ibuprofen hydroxylation.

Heterocyclic Compound Orexin 2 Receptor Agonist Narcolepsy Treatment

The USPTO published patent application US20260092033A1 for a heterocyclic compound as an orexin 2 receptor agonist for treating narcolepsy. Inventors include researchers from a Japanese pharmaceutical company. The application claims priority to Application No. 19287436 filed July 31, 2025. This is a standard pharmaceutical patent filing that does not impose regulatory obligations on third parties.

Indole Derivatives as Serotonergic Agents for CNS Disorders

USPTO published Application US20260092035A1 disclosing indole derivatives of general Formula (I) as serotonergic agents useful for treating CNS disorders including psychosis and mental illnesses. Inventor Abdelmalik Slassi filed the application on December 9, 2025 (Application No. 19413522). This patent application publication represents a routine intellectual property filing with no compliance obligations or regulatory deadlines for third parties.

Crystalline Benzamide Salt Forms for T-Type Calcium Channel Diseases

USPTO published patent application US20260092037A1 disclosing crystalline salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide useful for treating T-type calcium channel diseases including epilepsy, essential tremor, and major depressive disorder. The application (No. 19311876) was filed August 27, 2025, naming inventors David T. Jonaitis and Lisa McCracken.

Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

The USPTO published patent application US20260092038A1 disclosing novel cannabinoid receptor 1 (CB1) antagonists/inverse agonists for treating metabolic disorders including diabetes, dyslipidemia, cardiovascular disorders, obesity, and cancer. Invented by Marshall Morningstar, the application covers compound compositions and therapeutic uses. Filing date was September 26, 2025.

Novel Heterocyclic Compounds for Pharmaceutical Use

Hoffmann-La Roche Inc. published patent application US20260092076A1 for novel heterocyclic compounds with pharmaceutical use. The application covers compounds having general formula I with defined R1, R2, R3, A and W substituents, related compositions, and methods of using the compounds. Filing date was October 7, 2025, under Application No. 19351608.

VMAT2 Inhibitor Heterocyclic Compound and Preparation Method

The USPTO published patent application US20260091029A1 for a class of VMAT2 inhibitor heterocyclic compounds. The application, filed December 9, 2025 under Application No. 19414124, covers compounds represented by formula (I), their stereoisomers, and pharmaceutically acceptable salts. The inventors (Jingwei Tian, Rui Zhang, and seven others) also disclose preparation methods and applications for treating diseases related to VMAT2 and Sigma-1 receptors.

KRAS Inhibitor Heterocyclic Compounds for Cancer Treatment

USPTO published patent application US20260092075A1 for KRAS inhibitor heterocyclic compounds designed for cancer treatment. The application covers novel chemical compounds of specified formula, their pharmaceutical salts, and methods of using these compounds for treating cancer patients. Filing date was September 30, 2025.

Bifunctional degraders with electrophilic PROTACs

The USPTO has published a patent application (US20260083722A1) detailing bifunctional degraders comprising electrophilic PROTACs that engage DCAF1. The application was filed on May 19, 2023, and published with a projected application date of March 26, 2026.

Substituted Indazoles for Treating Animal Allergic Inflammatory Diseases

The USPTO has published a patent application detailing the use of substituted indazoles for the treatment and prevention of allergic and inflammatory diseases in animals. The application, filed on October 9, 2025, outlines specific compounds and their potential applications in veterinary medicine.

US Patent Application: Non-Aqueous Electrolyte, Battery, Device

The USPTO has published a new patent application (US20260088357A1) for a non-aqueous electrolyte, secondary battery, and electric device. The application, filed by CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED, details specific chemical compositions for electrolytes, including cyclic sulfate compounds and organic base additives. This publication represents a new disclosure in the field of battery technology.

Photoresist Molecular Group Structure, Synthesis, and Use Method

The USPTO has published a new patent application (US20260086460A1) for a bifunctional molecular group structure for photoresists, including a linker, PAG molecule, and PDQ molecule. The application also details synthesis and use methods for this structure, assigned to Shanghai Huali Integrated Circuit Corporation.

Psilocin Crystalline Forms Patent Application

The USPTO has published a patent application (US20260085039A1) detailing crystalline forms of psilocin, including salts and cocrystals. The application, filed by Jim Gilligan and Peter Guzzo, describes these forms as having improved physical properties like aqueous solubility and stability, suitable for various administration routes.